August 30th, 2014
John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.
March 15th, 2010
We welcome John J. McMurray, MD, lead author of the NEJM article on the valsartan component of the NAVIGATOR trial, to answer our questions about this angiotensin-receptor blocker (ARB). We encourage you to ask yours. Background: In the NAVIGATOR trial, 9306 patients with impaired glucose tolerance and established cardiovascular disease or CVD risk factors were randomized, […]